We investigated the mechanisms by which TAp73b and dominant-negative p73 (DNp73) regulate apoptosis. TAp73b transactivated the CD95 gene via the p53-binding site in the first intron. In addition, TAp73b induced expression of proapoptotic Bcl-2 family members and led to apoptosis via the mitochondrial pathway. Endogenous TAp73 was upregulated in response to DNA damage by chemotherapeutic drugs. On the contrary, DNp73 conferred resistance to chemotherapy. Inhibition of CD95 gene transactivation was one mechanism by which DNp73 functionally inactivated the tumor suppressor action of p53 and TAp73b. Concomitantly, DNp73 inhibited apoptosis emanating from mitochondria. Thus, DNp73 expression in tumors selects against both the death receptor and the mitochondrial apoptosis activity of TAp73b. The importance of these data is evidenced by our finding that upregulation of DNp73 in hepatocellular carcinoma patients correlates with reduced survival. Our data indicate that DNp73 is an important gene in hepatocarcinogenesis and a relevant prognostic factor.
Introduction
The discovery of a DNp73 (dominant-negative p73)-based p53-p73 interference network suggests that the p53 status of a tumor should no longer be regarded as the sole predictor of clinical outcome and therapeutic responsiveness.
TP53 is the prototype tumor suppressor gene in human cancer due to its proapoptotic and antiproliferative function in response to oncogenic stress. The p53 pathway is inactivated in the majority of human malignancies.
1 TP73, despite significant homology to p53, is not a classic Knudson-type tumor suppressor gene. [2] [3] [4] TP73-deficient mice lack a tumor phenotype 5 and inactivating mutations in patients suffering from cancer are extremely rare. 3 The expression of the TP73 gene is complicated by the presence of several splicing isoforms at the C-terminus (p73a-z) 2, 3, 6, 7 and of two distinct promoters, driving the expression of p53-like proteins containing the transactivation domain (TAp73), and inhibitory proteins lacking TA, called DTAp73 (the collective name for four different p73 TAdeficient forms, mainly DNp73). DNp73 acts as a potent transdominant inhibitor of TAp73 and wild-type p53. 3, 8 Thus, the TP73 locus encodes both a tumor suppressor (TAp73) and a putative oncogene (DNp73).
The finding that a significant percentage of tumors specifically select for dominant-negative p73 isoforms strongly argues for their oncogenic role during tumorigenesis. 8, 9 DNp73 cooperates with oncogenic Ras in transforming primary mouse embryo fibroblasts (MEFs) in vitro and in inducing MEF-derived fibrosarcomas in nude mice in vivo. 10 Furthermore, mice heterozygous for mutations in both p53 and p63 or p63 and p73 displayed higher tumor burden and metastasis compared to p53 þ /À mice. 11 Endogenous TAp73 is activated in response to a variety of chemotherapeutic drugs and gamma-irradiation in a pathway that depends on the non-receptor tyrosine kinase c-Abl. 12, 13 We have recently described a role for TAp63a in the induction of apoptosis and chemosensitivity. 14 The involvement of p63 and p73 in p53-mediated apoptosis is controversial. Whereas on the one hand the presence of p63 and p73 has been shown to be essential for p53 to induce apoptosis in fibroblasts following DNA damage, 15 results of a recent study indicate on the other hand, that at least in thymocytes, p53-dependent apoptosis occurs independently of p63 and p73.
Given the possible role of TAp73 and DNp73 isoforms in cancer, it is of great interest to determine how they regulate apoptosis, as the critical process which links tumor development, treatment sensitivity and clinical outcome.
We have analyzed the mechanisms of TAp73/DNp73-regulated apoptosis and their relevance for chemosensitivity and prognosis in hepatocellular carcinoma (HCC).
Our data suggest possible signaling pathways through which the balance between TAp73 and DNp73 regulates the apoptosis response of cancer cells, thereby playing a decisive role in the choice between elimination of cancer-prone cells versus hepatocarcinogenesis as well as between treatment sensitivity versus drug resistance. Of clinical importance, we show that DNp73 is a predictor of adverse outcome and a new prognostic factor in HCC. 
Results

TAp73b-induced apoptosis involves activation of caspases
Microarray analysis of TAp73b-mediated apoptosis
Since TAp73b was able to induce classical apoptosis ( Figure 1 ) and since TAp73 is a transcription factor, we decided to investigate the underlying molecular mechanisms by performing a gene array analysis. Following adenoviral TAp73b transfer the genes encoding for the death receptors CD95, TNF-R1, TRAIL-R1 and -R2 were found to be upregulated (Table 1) . Additional evidence for the involvement of receptor-mediated signaling in TAp73b-induced apoptosis was provided by the fact that the pro-caspase-8-binding adapter protein Fas-associated death domain (FADD) was found to be upregulated.
Activation of caspases is clearly involved in mediating TAp73b-induced downstream apoptosis signaling. Caspase-1, -2, -3, -4, -6, -8, -9 and -10 were found to be upregulated in response to TAp73b (Table 1) .
Furthermore, we identified the genes encoding the proapoptotic Bcl-2 family members BAD and BIK and the genes encoding BNIP3, HRK and RAD9 as targets for transcriptional upregulation in cells overexpressing TAp73b (Table 1) . Thus, microarray analyses provide evidence that TAp73b stimulates both, genes that regulate the extrinsic apoptosis pathway initiated by ligation of death receptors and genes that regulate the intrinsic/mitochondrial apoptosis pathway.
TAp73b triggers the extrinsic apoptosis pathway via activation of death receptors
We have previously shown that the CD95 gene is a transcriptional target of wt p53, whose expression is induced (Figure 2a) .
Importantly, FACS analysis revealed that overexpression of TAp73b led to an increase in the amount of CD95 displayed on the cell surface in Hep3B (Figure 2b and c) . This increase in CD95 expression was also observed in a second cellular model, in Saos2 cells (Figure 2d ). Saos2 cells are p53 negative and show no detectable levels of p63 and p73 at either mRNA or protein level.
The increased number of death receptors on the cell surface is likely to increase sensitivity of cancer cells towards apoptosis. We tested this hypothesis by treating Hep3B cells with agonistic anti-APO-1 antibody. Figure 2e shows that the antibody is in fact able to trigger cell death in TAp73b-overexpressing Hep3B cells, but not in cells infected with a control green fluorescent protein (GFP)-adenovirus. This indicates that TAp73b induces the expression of a functional CD95 death receptor on the cell surface.
TAp73 is a transcriptional activator of the CD95 gene
Upregulation of CD95 mRNA and protein by TAp73b might be due to direct transcriptional activation of the CD95 gene. Since most of the TAp73b-driven promoters seem to share p53-responsive elements, we investigated the possibility that TAp73b transactivates the CD95 gene via binding to the intronic p53-binding site 17, 18 ( Figure 3a ). This was carried out by transient transfection assays, employing plasmid p1142CD95-luc. Figure 3c shows that cotransfection of the TAp73 isoforms a, b, g and d significantly increased p1142CD95-luc activity. This supports the hypothesis that TAp73 can induce CD95 gene expression. The TAp73-dependent transactivation of the CD95 gene strictly depends on the intronic p53-binding site, as it is totally abrogated when using a CD95 luciferase construct ( Figure 3c ) with a mutated intronic p53-binding site (Figure 3b ). This argues strongly in favor of the conclusion that the CD95 gene is a direct transcriptional target of TAp73.
DNp73 is an efficient inhibitor of the transcriptional activity of TAp73 and inhibits both transactivation of the CD95 gene and apoptosis
As shown in Figure 4a , DNp73 is a strong inhibitor of TAp73-mediated CD95 gene transactivation. DNp73 is not able to transactivate the CD95 gene by itself. In addition, Figure 4b shows the capacity of the D84p73b isoform, which is functionally equivalent to the D2p73, D3p73 and D23p73 isoforms, 2 to abrogate TAp73-mediated transactivation of the CD95 gene. Furthermore, D84p73b blocks p53-mediated transactivation of the CD95 promoter ( Figure 4c ). Thus, interference with the CD95 gene transactivation-capacity of TAp73 and that of p53 constitutes a molecular mechanism by which N terminus-deleted p73-isoforms exert their antiapoptotic action. This implies that the presence of the DNp73 (or D84p73b) protein constitutes a dominant-negative effect controlling apoptosis in hepatoma cells. To test this hypothesis, we evaluated the regulation of apoptosis by DNp73. Hep3B cells undergo TAp73b-dependent cell death as assessed by FACS analysis. This apoptotic activity is completely abolished by the coexpression of D84p73b (Figure 4d ).
TAp73b engages mitochondrial apoptosis pathways
In order to further characterize the molecular mechanisms of TAp73-mediated apoptosis, we investigated the influence of To investigate the possible involvement of Bax in p73-induced apoptosis, we performed a transient transfection assay using a reporter plasmid (Bax-Pr/luc) containing the full-length Bax promoter placed upstream of a luciferase cDNA (Figure 5b ). Figure 5c shows that cotransfection of TAp73b significantly increased Bax-Pr/luc activity. Western blot analysis confirmed induction of endogenous Bax protein following rAd-TAp73b transfer (Figure 5d ). In addition, as shown by microarray analysis, BAD, BIK, BNIP3, HRK and RAD9 were induced (Table 1) . Thus, TAp73b contributes to apoptosis by inducing the expression of several proapoptotic genes involved in mitochondrial signaling.
Blocking TAp73b by rAd-D84p73b significantly decreased Bax-Pr/luc activity. Furthermore, D84p73b did also block p53-mediated transactivation of the Bax promoter ( Figure 5e ). Thus, in addition to interference with the death receptorapoptosis activity of TAp73b, N terminus-deleted p73-isoforms exert their antiapoptotic action also on mitochondrial apoptosis signaling pathways.
TAp73b sensitizes cancer cells towards chemotherapy
p53 is frequently mutated in human cancer. This has been implicated in resistance towards chemotherapy. We therefore next investigated if TAp73b restores chemosensitivity of cancer cells.
First, we found that chemotherapeutic agents (bleomycin, mitoxantrone and doxorubicin) induce endogenous TAp73 expression in Hep3B cells (Figure 7a ). This is in accordance with data obtained in other cell lines. 19 We then tested if there is a synergistic effect of TAp73b and chemotherapeutic agents on the induction of cell death. We infected Hep3B (p53-/-), HepG2 (wt p53) AGS (wt p53) and Saos2 (p53-/-) cells with an adenoviral TAp73b (5 and 10 MOI). Then we exposed the cells to different doses of bleomycin. Figure 6a shows that rAd-TAp73b enhances cell killing by bleomycin. All Hep3B cells were transfected with 1 mg of plasmid p1142CD95-luc together with 100 ng of either a TAp73a, b, g or D-plasmid, a p53-plasmid, or an equivalent amount of empty vector alone or together with the respective DNp73-or D84-isoform. Presented is the fold TAp73-or p53-dependent activation of each reporter plasmid, calculated relative to the value obtained with the same reporter in the absence of the respective TAp73-isoform or of p53. DNp73 (a) and D84p73b (a) were not able to transactivate the CD95 gene. Moreover, they act as dominant-negative being able to repress the ability of TAp73 to drive the CD95 gene. In addition to their ability to inhibit TAp73-mediated transactivation of the CD95 gene, the DN-and D84 isoforms of p73 inhibit wt p53-induced transactivation of the CD95 gene (c). Assays were performed in triplicates in five independent experiments. One representative experiment is shown (mean7S.D., n ¼ 3). (d) DN-and D84 isoforms of p73 inhibit specific apoptosis induced by TAp73b. Hep3B cells were transduced for 72 h either with rAd TAp73b (10 MOI) or rAd D84p73b (10 MOI). Data obtained in three separate experiments were averaged, presented is mean7S.D., n ¼ 9
TAp73/DNp73 as predictor of chemosensitivity M Müller et al cancer cell lines tested displayed an increased responsiveness towards cell death after adenoviral TAp73b transfer, independent of their p53 status. A balanced two-way analysis of variance (ANOVA) revealed a highly significant synergistic interaction (Po0.0001) between TAp73b and bleomycin in induction of cell death. The observed synergy of TAp73b and chemotherapeutic drugs was due to a cooperative effect on induction of specific apoptosis (Figure 6b) . FACScan s analysis 20 revealed that TAp73b significantly increased drug-induced apoptosis of Hep3B and Saos2 cells (Po0.0001). DAPI staining also illustrated the cooperative effect on the induction of cell death (Figure 6c) .
We further analyzed the mechanisms contributing to the enhanced chemosensitivity conferred by TAp73b. The synergy of TAp73b and bleomycin turned out to be due to a cooperative action at different levels of apoptosis signaling, namely at the death receptor and the mitochondrial level, enhancing apoptosis mediated by the CD95 system ( Figure  6d and e) as well as apoptosis mediated by mitochondrial activation (Figures 6f and g and 7e) . CD95 ligand mRNA was induced upon bleomycin treatment (Figure 6d and reported previously, 17, 18, 21 ) but not by TAp73b, whereas TAp73b stimulated upregulation of CD95 receptor mRNA. Apoptosis following adenoviral TAp73b-transfer and bleomycin treatment was partially blocked by an antagonistic anti-CD95L Ab (NOK-1), indicating a role of a CD95L/CD95 interaction in the death process (Figure 6e) . Thus, the observed synergy of TAp73b and chemotherapy may in part result from enhanced CD95 expression (due to TAp73b) triggered by upregulated CD95 ligand (due to chemotherapy). In addition, we show a cooperative action of TAp73b and bleomycin on mitochondrial apoptosis. FACScan s analysis showed that the change of the mitochondrial membrane potential caused by TAp73b was significantly increased by addition of bleomycin (Figure 7e ). The cooperative action of TAp73b and bleomycin on mitochondrial apoptosis is further evidenced by the fact that combined treatment led to a significant increase of the transactivation of the Bax gene (Figure 6f ). This was validated on protein level; combined treatment led to a further increase of endogenous Bax protein (Figure 6g ).
DNp73 confers drug resistance to p53-deficient tumor cells
Since TAp73 and DNp73 show opposite effects on apoptosis induction, we investigated if DNp73 interferes with chemotherapy-induced apoptosis.
Both, endogenous TAp73 and DNp73 are upregulated in response to DNA damage by bleomycin, mitoxantrone and doxorubicin in Hep3B cells (Figure 7a and b) . D84p73b (Figure 7c ). Interference of DNp73 with apoptosis sensitivity can take place at several levels of apoptosis signaling. As shown in Figure 4 , DNp73 can directly interfere with the transcriptional activation function of p53 and TAp73 and consequently inhibit transactivation of the CD95 gene by p53 or TAp73. Furthermore, resistance towards chemotherapy by DNp73 can be imposed at the caspase-, and the mitochondrial level of apoptosis signaling. Figure 7d shows that rAd-D84p73b inhibits bleomycin-induced activation of caspase-3, -8, and -9 class of proteases. Adenoviral transfer of D84p73b strongly reduces mitochondrial activation induced by bleomycin and TAp73b as measured by Bax reporter assays and FACScan s analysis following JC-1 staining (Figure 5e and 7e) . Repression of TAp73b-mediated transactivation of the Bax promoter was one mechanism by which DNp73 acts as dominant-negative on mitochondrial apoptosis signaling (Figure 5e ). Even though we cannot exclude a direct activity of DNp73 on the mitochondria, it is more likely that the effect of DNp73 on mitochondria is also due to its interference with TAp73-mediated transactivation, albeit other genes are involved (Table 1) . This supports the hypothesis that the ratio of the two isoforms TAp73/DNp73 is an important determinant of clinical response to chemotherapy. This prompted us to further analyze the clinical significance of DNp73 expression in patients with HCC.
Clinical impact of DNp73 overexpression: DNp73 is a prognostic marker in patients with HCC
Western blot analysis revealed that TAp73 and DNp73 are specifically expressed in tumor tissue, but not in nonneoplastic liver tissue. Hereby, TAp73 and DNp73 seemed By immunostaining, our antibody raised specifically against DNp73, identified 31 out of 84 (37%) of the HCCs to overexpress DNp73 (Table 2, Figure 9a and b) . Within these tumors, we observed a strong immunoreactivity of the tumor cell nuclei. In the case of surrounding, non-neoplastic cirrhotic liver tissue, normal hepatocytes were seen to be occasionally positive for DNp73. In contrast to the corresponding tumors, however, in nontumorous tissue only very few nuclei (o1%) expressed DNp73 (Figure 9c) . p53 mutational analysis revealed that 46% (39/84) of these HCC patients carried p53 mutations. There was no correlation between DNp73 overexpression and the p53 mutational status ( Table 3) .
The survival analysis took into account DNp73 positivity (defined by immunohistochemistry), UICC tumor stage and Figure 8 Western Blot analysis of DNp73 and TAp73 expression in six HCCs ('T') and corresponding non-neoplastic liver tissue ('N') using our specific antibodies. TAp73 and DNp73 are distinctively expressed in tumor tissue, but not in non-neoplastic liver tissue Figure 9 Immunohistochemical demonstration of DNp73 protein in hepatocellular carcinoma and in non-neoplastic liver tissue using our specific antibody. Table 2) . Of clinical importance is our finding of a significantly shorter survival time of patients with tumors overexpressing DNp73 compared to patients whose tumors were DNp73 negative (Po0.005, log-rank test) ( Table 2 ).
Discussion
Findings obtained in the present study allow us to propose a model that links the regulation of apoptosis by the relative expression of TAp73 and DNp73 to chemosensitivity and clinical outcome in HCC (Figure 10 ). Our data provide three new findings: (1) the identification of new target genes of TAp73/DNp73-regulated apoptosis pathways, (2) the molecular mechanisms of TAp73/DNp73 in chemosensitivity and (3) the characterization of DNp73 as a new prognostic marker for patients with HCC.
Our results support a two-pathway model for the TAp73-apoptotic response in hepatoma cells. Here, we show that TAp73b is involved in the activation of both, the extrinsic/ death receptor-mediated apoptosis pathway as well as the intrinsic/mitochondria-mediated apoptosis pathway, pathways 1 and 2, respectively (Table 1 and Figure 10 ).
TAp73b can trigger each of the major death receptor systems, the CD95-, the TNF-R-and the TRAIL-R-system. We identified the CD95 gene as a transcriptional target of TAp73b via the intronic p53 enhancer. We show that TAp73-dependent transactivation of the CD95 gene depends on the intronic p53 binding site, as it was totally abrogated when we mutated the intronic p53-binding site of the CD95 gene. The TRAIL-R1 and -R2 genes are other death receptor genes that harbor p53-binding elements. 22, 23 Thus, TAp73b-mediated transcriptional activation of the TRAIL-R1 and -R2 genes might also be exerted via binding to p53-responsive elements. Furthermore, we found TNF-R1 and TNF to be upregulated by TAp73b. This is in line with recent findings that c-ABL and p73 contribute to apoptosis induced by TNFa, in addition to their role in promoting DNA damage-associated cell death. 24 As for the CD95 system, CD95 ligand mRNA was induced upon concomitant treatment with cytostatic drugs but not by TAp73b alone. Thus, TAp73-mediated increases in CD95 expression may lead to apoptosis in a CD95 ligandindependent fashion. Spontaneous multimerizing of overexpressed CD95 and TNFR1 has been reported previously to result in the induction of CD95-and TNF-like effects, independent of the respective ligand, suggesting that the self-association of the death domain suffices to trigger downstream signaling and apoptosis. 25, 26 In addition to its direct effect on death receptor-mediated apoptosis, TAp73b can contribute to apoptosis by inducing the expression of several pro-apoptotic proteins acting at the mitochondrial level. Using microarray analysis we identified BAD, BIK, BNIP3, HRK and RAD9 to be upregulated in cells overexpressing TAp73b. Similar to p53, TAp73 was able to transactivate the Bax promoter in hepatoma cells and to induce an increase of endogenous Bax protein levels. This is in line with previous findings from our group in a different cellular system (Saos2 cells). 27 Thus, TAp73, like p53, 1 engages the major apoptotic pathways in the cell stimulating both death receptor signaling and apoptosis emanating from mitochondria. Furthermore, our results show a relevant role for TP73 in chemosensitivity. Both, endogenous TAp73 and DNp73, are upregulated in response to DNA damage by bleomycin, mitoxantrone and doxorubicin. TAp73b significantly enhances the apoptosis-inducing effect of chemotherapeutic drugs in a variety of solid cancer cell lines. On the contrary, the N terminus-deleted p73 isoform predominantly detected in cancer, D84p73, as well as the isoform produced by the second promoter, DNp73, confers drug resistance to hepatoma cells. Interference of DNp73 with death by apoptosis in tumor cells after treatment with anticancer agents can take place at several levels of apoptosis signaling. Resistance towards chemotherapy imposed by DNp73 occurred at least in part by downregulation of the CD95 gene. Our data show that direct interference with the CD95 gene transactivation function of TAp73 and of p53 is one molecular mechanism by which DNp73 exerts its antiapoptotic and oncogenic function. 8, 10, 28 This inhibitory effect of DNp73 is not restricted to the CD95 gene. There may exist additional proapoptotic genes (harboring p53 binding elements) whose expression is downregulated by DNp73, contributing to tumor progression and a worse patient outcome. We identified the Bax promoter to be repressed by DNp73. Thus, resistance towards apoptosis by DNp73 is also imposed by inhibition of mitochondrial apoptosis pathways. Furthermore, DNp73 strongly inhibited chemotherapy-induced activation of caspase-3, -8 and -9. Of note, our data couple the disruption of apoptosis at the death receptor-and mitochondrial level by Figure 10 Model of TAp73/DNp73-regulated apoptosis. Upon DNA damage, TAp73 activates both, the death receptor-(pathway 1) and the mitochondrial-(pathway 2) apoptosis pathway. DNp73 is a strong inhibitor of both pathways Emerging evidence from the analysis of primary human tumors shows that deregulated DNp73 expression is rather frequent. 8, 9 In neuroblastoma, which is almost exclusively wild-type for p53, a correlation of DNp73 status with the clinical outcome was seen. 9 In a series of 193 patients with HCC, we have previously shown detectable (high) p73 by in situ hybridization and immunohistochemistry in 32% of the tumors, whereas all normal tissue had undetectable p73 levels. 29 Many of the (early) p73 overexpression studies in human cancers determined total p73 levels, because the antibodies used could not distinguish between TA and DNp73. We have generated highly specific antibodies 30 and we show here for the first time that it is the DNp73 isoform, which is upregulated in HCC. Our antibody raised specifically against DNp73, identified 31 out of 84 (37%) of patients with HCC to overexpress DNp73 in their tumor tissue. Importantly, we provide the first evidence that DNp73 upregulation in HCC is correlated with a poor prognosis. Patients with tumors overexpressing DNp73 exhibited a significantly shorter survival time compared with patients whose tumors were DNp73 negative (Po0.005 logrank test). This is an important and clinically relevant finding, which suggests the use of DNp73 status as a prognostic marker for patients with HCC.
Our finding that a significant percentage of HCCs select for dominant-negative p73 isoforms strongly argues for their oncogenic role during hepatocarcinogenesis. Preferential upregulation of DNp73 in HCCs might impose oncogenic activity that specifically interferes with the tumor suppressor function of wild-type p53 and TAp73 disabling major apoptosis pathways (death receptor-and mitochondrial pathways), as we have shown in vitro.
Molecular links between apoptosis, tumorigenesis and drug resistance provide the foundation for new therapeutic approaches and for a targeted cancer therapy. Our results show that p53 is not the only component in predicting prognosis and response to chemotherapy, but instead the status of a network that contains p53, p73 and p63.
14 Therapeutic modulation of TAp73/DNp73 and mutant p53 levels might be used to target the large percentage of human tumors that harbor p53 mutations and/or overexpress DNp73. One might predict that interfering with the expression or function of DNp73 and/or mutant p53 and/or DNp63 in tumor cells may render such tumors more responsive to therapy and reduce their aggressiveness and metastatic capacity.
Materials and Methods
Cell lines
We used Hep3B (human liver carcinoma, deficient in p53 [p53À/À]), HepG2 (human hepatoblastoma, wild-type (wt) p53), AGS (human gastric adenocarcinoma, wt p53) and Saos2 (human osteosarcoma, p53À/À). Hep3B cells were maintained in MEM (Invitrogen, Karlsruhe, Germany), HepG2 and AGS in DMEM (Gibco BRL, Eggenstein, Germany) and Saos2 in a 1:1 mixture of Ham's F-12/DMEM (Biochrom, Berlin, Germany). Medium was supplemented with 10% FCS (Biochrom), 10 mM HEPES pH 7.3 (Invitrogen), 2 mM L-Glutamine (Invitrogen) and 100 mg/ml Gentamycin (Invitrogen).
Treatment with cytostatic drugs
Cells were treated with bleomycin at a dose range of 0.3-300 mg/ml or with doxorubicin at a dose range of 0.005-0.5 mg/ml or with mitoxantrone at a dose range of 0.1-1 mg/ml for 6 h up to 72 h. The concentrations relevant for therapy are 1.5-3 mg/ml for bleomycin, 0.001-0.02 mg/ml for doxorubicin, and 0.03-0.5 mg/ml for mitoxantrone in patients' sera.
Treatment with IgG3 anti-APO-1
The CD95 (Apo-1/Fas) receptor was stimulated with the monoclonal antibody anti-APO-1 IgG3, k, at a concentration of 1 mg/ml as described. 18 
Adenoviral constructs and transduction
Replication deficient adenoviral vectors were generated according to the method of He et al. 31 The vectors either encoded the complete human wt p53 cDNA (rAd-p53), TAp73b cDNA (rAd-TAp73b) or D84p73b cDNA (rAd-D84p73b), together with the GFP, or the GFP alone (rAd-GFP), each under the control of the cytomegalovirus immediate/early gene (CMV) promoter. At a MOI of 10, an infection rate of 80-90% of the cells was obtained. Cells were seeded in six-well plates 24 h before transduction. Then adenoviruses (rAd-GFP, rAd-p53, rAd-TAp73b or rAd-D84p73b) were added to the culture medium and cells were incubated with the virus for 4 h.
Plasmids
A construct was generated containing 3.2 kb of the physiological sequence of the CD95 gene, that is, the 3 0 part of the promoter, the complete exon 1 and the 5 0 part of intron 1. This plasmid is denoted p1142CD95-luc and has been employed in all the transient transfection assays presented. Mutants of the intronic p53-binding site of p1142CD95-luc 18 were established using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, Heidelberg, Germany).
The Bax-luciferase reporter plasmid (Bax-Pr/luc) and TAp73a, b, g, d; DNp73b and D84p73b have been described previously. 7, 32, 33 Transfections Cells were transfected by the use of calcium-phosphate. After 18 h medium was changed. After 2 h, cells were infected with the adenovirus at a MOI of 10. After 24 h, cells were harvested and assayed for luciferase activity as described by the manufacturer (Promega, Heidelberg, Germany).
DAPI staining
DAPI (4 0 ,6-diamidino-2-phenylindole, Sigma, Munich, Germany) staining of cellular DNA, was performed as described.
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Cytotoxicity MTT-assay
Cell viability was determined by a colorimetric MTT-assay as described. 17 
Detection of apoptosis
Apoptosis was assessed by fluorescence-activated cell sorting (FACS) analysis carried out in a FACScan s flow cytometer (Becton Dickinson, Heidelberg, Germany) using the CELLQuest s software system. Quantification of DNA fragmentation was performed by FACS analysis of propidium iodide-stained nuclei. 18, 20 To block apoptosis, the broad spectrum caspase inhibitor ZVAD-FMK 
Detection of CD95 ligand (CD95L) and CD95 receptor (CD95) mRNA
Total cellular RNA was prepared from 3 Â 10 6 cells treated with bleomycin and/or 10 MOI rAd-TAp73b, using the Rneasy-kit s (Qiagen, Hilden, Germany). PCR conditions and primers have been described previously.
17,18
Detection of CD95 (APO-1/Fas) Cell surface expression of the CD95 receptor was assessed by FACScan s . Hep3B or Saos2 cells were incubated for 30 min with anti-CD95 receptor antibody (anti-APO-1 IgG3, k) and washed with PBS ( þ 10% FCS). PE-labeled affinity purified F(ab)' 2 fragment goat antimouse IgG Fc antibody (Dianova, Hamburg, Germany) was used as secondary detecting reagent. To examine staining specificity of the second antibody cells were incubated with isotype control (IgG3) alone.
Immunodetection of Bax, TAp73 and DNp73
For immunodetection of Bax, we applied the mouse anti-Bax monoclonal antibody sc-7480 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). For the analysis of TAp73 and DNp73 expression in hepatoma cells and in liver tissue from patients with HCC, we used highly specific antibodies raised in rabbits against Sam and DN domains, see below 'Immunohistochemical analysis and Western blot of tissue samples'. 30 
Determination of mitochondrial membrane potential
Hep3B cells were incubated with 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide (JC-1, 5 mg/ml; Molecular Probes, Eugene, OR, USA) for 20 min at room temperature in the dark, washed twice and analyzed by FACScan s as described. 14 
Microarray analysis
We have developed high-density cDNA arrays in cooperation with the Department of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany. Hep3B cells were infected with 10 MOI rAd-TAp73b or rAd-GFP respectively, and RNA was extracted after 12, 24, 36 and 48 h using the Quiagen RNAeasy-kit (Hilden, Germany). Two independent experiments were performed. Extracted RNA was checked for quality using Agilent 2100 bioanalyzer (Ambion, Waldbronn, Germany). Total RNA was labeled and rewritten to cDNA in a reverse transcriptase reaction, containing 100 ng/ml oligodT15 primer, 5 mmol DTT, 1 mmol of dATP, dDTP, dGTP and [33P]dCTP (Amersham, Freiburg, Germany) and 10 U superscript II reverse transcriptase (Gibco BRL, Eggenstein, Germany). cDNA was hybridized to nylon membranes containing PCR-products of 1066 specific cDNA clones. These clones represent genes that are involved in apoptosis and immunological signaling pathways. In total, 36 clones, of which three representative clones are shown in Table 1 , served as positive controls. Array preparation and quality control was performed by the German Resource Center for Genome Research (RZPD, Berlin/ Heidelberg, Germany). These arrays are now commercially available at www.rzpd.de (Immunofilter, RZPD). Hybridization was performed overnight at 681C in Expresshyb s hybridization solution (Clontech, Heidelberg, Germany). Three hybridizations were performed for each experiment. After washing for 1 h in SDS-SSC buffer, arrays were exposed to phosphoimager screens and subsequently analyzed using a FujiBas s phosphoimager. We used Visual Grid Software (GPC Biotechnology, Martinsried, Germany) for matching the files. Expression levels were normalized over all positive spots using J-Express s software (J-Express V2.1, Molmine bioinformatics software solutions, Bergen, Norway) and subsequently evaluated by SAM (significance analysis of microarrays) software, which identifies genes whose expression has significantly changed. 34 
Patients and tissue samples
In total, 84 patients with HCC undergoing partial hepatectomy were included in a retrospective study. All patients underwent surgery with curative intent (R0 resections). Patients who received orthotopic liver transplantation were excluded from the study. No patient received preoperative or adjuvant chemotherapy or radiotherapy. Each tumor was evaluated with regard to typing, staging and Edmondson grading. Tumor typing and staging were performed by use of criteria of the World Health Organization 35 and the International Union Against Cancer (UICC), 36 respectively. The patients and their pathohistological data are summarized in Table 2 . The slides were evaluated by two observers who were blinded to clinical and pathologic information.
Immunohistochemical analysis and Western blot of tissue samples
We have generated new antibodies with p73 isoform specificity, recognizing only the TA domain of p73 or only DN isoforms. 30 The rabbit polyclonal antibody against DNp73 was used for immunohistochemical analysis of 84 HCCs and corresponding nonneoplastic liver tissue as described before. 29 Western blot was performed using the rabbit polyclonal antibody against DNp73 and the monoclonal antibody against the TA domain of p73 as described previously. 
Statistical analysis
To examine whether synergy between rAd-TAp73b transfer and concurrent chemotherapeutic treatment is observed, a balanced twoway ANOVA (model with fixed effects) was performed. Furthermore, we applied MANOVA (multivariate analysis of variance) and Wilcoxon analysis to test for statistical significance. The log-rank test was used to detect differences between survival curves for stratified variables. Statistical analysis was carried out using the SAS software system (SAS Institute Inc., Cary, NC, USA).
